825 Industrial Road
San Carlos, CA 94070
650 597 5002
Full-time employees: 123
|Dr. Robert Alexander Ph.D.||CEO & Director||1.46M||N/A||1970|
|Dr. Adam L. Tomasi Ph.D.||Pres||1.11M||N/A||1970|
|Mr. Baird Radford III||Chief Financial Officer||708.26k||N/A||1970|
|Dr. Henrik Sandvad Rasmussen M.D., Ph.D.||Strategic Advisor||N/A||N/A||1959|
|Dr. Craig Paterson M.D.||Chief Medical Officer||N/A||N/A||1965|
|Dr. Brad Youngblood Ph.D.||Head of Research & Pre-Clinical Devel.||N/A||N/A||N/A|
|Ms. Mary Cromwell Ph.D.||SVP & Head of Technical Operations||N/A||N/A||N/A|
|Mr. Alan Chang||Director of Medical Affairs & Data Analytics||N/A||N/A||N/A|
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.